2-(2-Propoxyphenyl)purine-6,8-dione | 329351-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-(2-Propoxyphenyl)purine-6,8-dione
• 英文别名: 2-(2-propoxyphenyl)-1H-purine-6,8-dione
• CAS: 329351-36-2
• 化学式: C₁₄H₁₂N₄O₃
• 分子量: 284.274
• InChiKey: RVFPTRVSSFXHBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  92.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5,6-二氨基-2-(2-丙氧苯基)-4(1H)-嘧啶酮 在 N,N'-羰基二咪唑 作用下， 以 甲苯 为溶剂， 生成 2-(2-Propoxyphenyl)purine-6,8-dione
  参考文献：
  名称：

  Purinone derivatives which have bronchodilator, vasodilator and

  摘要：

  本发明涉及具有支气管扩张剂、血管扩张剂和抗过敏活性的嘌呤酮衍生物。该发明的化合物是2-(2-丙氧基苯基)-6-嘌呤酮。

  公开号：

  US04885301A1

文献信息

• Purinone derivatives which have bronchodilator, vasodilator and
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04885301A1

  公开（公告）日：1989-12-05

  This invention relates to purinone derivatives which have bronchodilator, vasodilator and anti-allergic activities. A compound of the invention is 2-(2-propoxyphenyl)-6-purinone.

  本发明涉及具有支气管扩张剂、血管扩张剂和抗过敏活性的嘌呤酮衍生物。该发明的化合物是2-(2-丙氧基苯基)-6-嘌呤酮。
• 2-Phenylpurinone derivatives, processes for their preparation, and their use as well as intermediates
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0293063A1

  公开（公告）日：1988-11-30

  Compounds of the formula (1) : and pharmaceutically acceptable salts thereof are described, wherein R¹ is C1-6alkyl or C2-6alkenyl, and R² is hydrogen or hydroxy. These compounds have vasodilator, bronchodilator and anti-allergic properties. Pharmaceutical compositions are described as are methods of use. Processes for the preparation of the compounds of the formula (1) are described.

  描述了式 (1) ： 及其药学上可接受的盐类，其中 R¹ 是 C1-6 烷基或 C2-6 烯基，R² 是氢或羟基。 这些化合物具有血管扩张、支气管扩张和抗过敏特性。此外，还介绍了药物组合物和使用方法。描述了制备式（1）化合物的工艺。
• Purine compounds, process for their preparation and pharmaceutical compositions
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0352960A2

  公开（公告）日：1990-01-31

  Compounds of the formula (1): and pharmaceutically acceptable salts thereof, wherein R¹ is C???alkyl, C???alkenyl, C???cycloalkylC???alkyl, phenylC???alkyl or C???alkyl substituted by 1 to 6 fluoro groups; R² is hydrogen, hydroxy, C???alkyl, phenyl, mercapto, C???alkylthio, CF? or amino; R³ is hydrogen, nitro, amino, C???alkanoylamino, C???­alkoxy, C???alkyl, halo, SO?NR?R?, CONR?R?, cyano or C???alkylS(O)n; R? and R? are independently hydrogen or C???alkyl; and n is 0, 1 or 2; provided that R³ is not hydrogen when R¹ is C???alkyl or C???alkenyl and R² is hydrogen or hydroxy. Processes for their preparation, pharmaceutical compositions comprising them and their use as medicaments are described.

  式（1）的化合物： 及其药学上可接受的盐，其中 R¹ 是 C???烷基、C???烯基、C???环烷基 C???烷基、苯基 C???烷基或被 1 至 6 个氟基团取代的 C??烷基； R² 是氢、羟基、C??烷基、苯基、巯基、C??烷硫基、CF?或氨基； R³ 是氢、硝基、氨基、C???烷酰氨基、C???烷氧基、C??烷基、卤素、SO?NR?R?、CONR?R?、氰基或 C??烷基S(O)n； R? 和 R? 独立地为氢或 C??烷基；以及 n 是 0、1 或 2； 当 R¹ 为 C???烷基或 C???烯基，且 R² 为氢或羟基时，R³ 不是氢。本文介绍了它们的制备方法、包含它们的药物组合物以及它们作为药物的用途。
• EP0352960B1
  申请人：——

  公开号：EP0352960B1

  公开（公告）日：1994-10-26
• US4885301A
  申请人：——

  公开号：US4885301A

  公开（公告）日：1989-12-05